пятница, 15 апреля 2016 г.

Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital

Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital


The brokerage set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. Chardan Capital's target price suggests a potential upside of 91.08% from the company's previous close.



from Biotech News